ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
- ABL Bio and GSK enter into a multi-program agreement to develop…
Total Investment of Approx. USD 11.4 Million in Schistosomiasis Diagnostics and R&D Projects for NTDs With Partners Including Drugs & Diagnostics for Tropical Diseases and Medical & Biological Laboratories
TOKYO, March 18, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced…
IN8bio Announces Advanced Gamma-Delta () T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
March 03, 2025 09:28 ET | Source: IN8bio, Inc Proprietary platform represents…
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris
February 27, 2025 19:05 ET | Source: Nxera Pharma Cenerimod is a…
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe…
Partnership Established to Advance WHO’s Road Map for Neglected Tropical Diseases 2021-2030
TOKYO and GENEVA, Dec. 11, 2024 /PRNewswire/ -- The Global Health Innovative…
Partnership Established to Advance WHO’s Road Map for Neglected Tropical Diseases 2021-2030
TOKYO and GENEVA, Dec. 11, 2024 /PRNewswire/ -- The Global Health Innovative…
Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases
HERLEV, Denmark, Nov. 11, 2024 /PRNewswire/ -- Nordic Bioscience, a leading biomarker company,…
Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases
HERLEV, Denmark, Nov. 11, 2024 /PRNewswire/ -- Nordic Bioscience, a leading biomarker company,…